Clinical Outcomes After Unrestricted Implantation of Everolimus-Eluting Stents

JACC: Cardiovascular Interventions

Volumn 2, Issue 12, 2009, Pages 1219-1226

  Latib, Azeem ^a,c   Ferri, Luca ^a   Ielasi, Alfonso ^a   Godino, Cosmo ^a,b   Chieffo, Alaide ^a   Magni, Valeria ^a   Bassanelli, Giorgio ^a   Sharp, Andrew S P ^b   Gerber, Robert ^b   Michev, Iassen ^a,b   Carlino, Mauro ^a   Airoldi, Flavio ^a   Sangiorgi, Giuseppe M ^b   Montorfano, Matteo ^a   Colombo, Antonio ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b EMO GVM CENTRO CUORE COLUMBUS   (Italy)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

drug eluting stent; everolimus eluting stent; off label; outcomes; real world

Indexed keywords

EVEROLIMUS;

ADULT; AGED; ARTICLE; BARE METAL STENT; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; PATIENT SAFETY; PRIORITY JOURNAL; RISK ASSESSMENT; STENT THROMBOSIS; THERAPY EFFECT; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 72149121821     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.09.014     Document Type: Article

References (22)

1. Torguson R., and Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Xience V Everolimus-Eluting Coronary Stent. Am J Cardiol 102 (2008) 1624-1630
2. Stone G.W., Midei M., Newman W., et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299 (2008) 1903-1913
3. Ruygrok P.N., Desaga M., Van Den Branden F., et al. One year clinical follow-up of the XIENCE-V everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. EuroIntervention 3 (2007) 315-320
4. Serruys P.W., Ong A., Piek J.J., et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention 1 (2005) 58-65
5. Serruys P.W., Ruygrok P.N., Neuzner J., et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2 (2006) 286-294
6. Tsuchida K., Piek J.J., Neumann F.J., et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (the SPIRIT FIRST Trial). EuroIntervention 1 (2005) 266-272
7. Qasim A., Cosgrave J., Latib A., and Colombo A. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications. Am J Cardiol 100 (2007) 1619-1624
8. Roy P., Buch A.N., Javaid A., et al. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Am J Cardiol 101 (2008) 293-299
9. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stents thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007) 745-754
10. Cosgrave J., Melzi G., Corbett S., et al. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 49 (2007) 2320-2328
11. Cosgrave J., Agostoni P., Ge L., et al. Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions. Am J Cardiol 96 (2005) 1663-1668
12. Lemos P.A., Serruys P.W., van Domburg R.T., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 (2004) 190-195
13. Stone G.W., Midei M., Newman W., et al., SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents. Two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 119 (2009) 680-686
14. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation 116 (2007) 2634-2653
15. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
16. Applegate R.J., Sacrinty M.T., Kutcher M.A., et al. "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol 51 (2008) 607-614
17. Beohar N., Davidson C.J., Kip K.E., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
18. Grines C.L. Off-label use of drug-eluting stents putting it in perspective. J Am Coll Cardiol 51 (2008) 615-617
19. Marroquin O.C., Selzer F., Mulukutla S.R., et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 358 (2008) 342-352
20. Serruys P.W., Morice M.C., Kappetein A.P., et al., SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 (2009) 961-972
21. Joner M., Nakazawa G., Finn A.V., et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52 (2008) 333-342
22. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008